The short answer
Incretin agonists have moved well beyond weight and glucose. SELECT demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide in 17,604 participants. Further indications including heart failure with preserved ejection fraction, chronic kidney disease and peripheral artery disease have followed or are under regulatory review.
Key facts
- SELECT
- 17,604 participants, 20% MACE reduction
- SELECT population
- BMI ≥27, established CVD, no diabetes
- HFpEF
- Under FDA review for semaglutide
- HFpEF signal
- NYHA class improvement 32.6% vs 21.5%
- Kidney disease
- FLOW trial: renal events and mortality
- Peripheral artery disease
- Under review; walking distance endpoint
- Retatrutide
- CVD and kidney trials within TRIUMPH
Why cardiovascular outcomes changed the category
Weight reduction is a surrogate endpoint. It is assumed to predict benefit, but assumption is not demonstration, and obesity medicines have a long history of failing on hard outcomes. SELECT tested the real question directly in 17,604 people aged 45 or over with a BMI of 27 or above and established cardiovascular disease but no diabetes, across 41 countries, and found a 20% reduction in major adverse cardiovascular events. That converted the class from plausible to demonstrated.
The finding that complicated the story
Post-hoc analysis of SELECT suggested the cardiovascular benefit was not fully explained by the amount of weight lost. If correct, incretin agonism is doing something to cardiovascular risk beyond making people smaller. That would be a different claim about the mechanism, and one that remains under investigation rather than settled.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Heart failure with preserved ejection fraction
HFpEF has been an unusually difficult indication with few effective options. Semaglutide has been under FDA review for HFpEF with obesity, with a prespecified analysis reporting that 32.6% of treated participants improved by at least one NYHA functional class against 21.5% on placebo. Functional class is a patient-relevant measure rather than a laboratory surrogate, which is part of why it drew attention.
Kidney outcomes
The FLOW trial reported reductions in renal events, major adverse cardiovascular events and mortality in people with chronic kidney disease and type 2 diabetes. Kidney and cardiovascular risk are tightly linked, and a compound acting on both is more valuable than one acting on either alone. Retatrutide's programme includes both a cardiovascular outcomes study and a dedicated renal-function trial.
Peripheral artery disease
Semaglutide has been submitted for peripheral artery disease in type 2 diabetes, on trial data reporting improved walking distance and quality of life. Walking distance is a direct functional measure, and PAD is a condition where symptomatic improvement is what patients actually notice.
How to read this expansion sceptically
Each indication rests on its own trial and its own endpoints, and none transfers automatically to another compound in the class. Tirzepatide produces greater weight reduction than semaglutide but does not inherit SELECT's cardiovascular result; that evidence belongs to the molecule that was tested. Outcome data takes years and large populations to generate, which is why the newest and most effective compounds have the least of it.
Frequently asked questions
Does tirzepatide have the same cardiovascular evidence as semaglutide?
No. SELECT tested semaglutide. Outcome evidence belongs to the compound tested and does not transfer across a drug class.
Is the cardiovascular benefit just from weight loss?
Post-hoc analysis of SELECT suggested it was not fully explained by weight reduction, but that remains under investigation rather than established.
Are these indications approved in the UK?
Approvals differ by regulator, indication and product. Several submissions described here have been under review rather than authorised.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedSELECT: Semaglutide and cardiovascular outcomes. NEJM 2023 (PMID 37952131)pubmed.ncbi.nlm.nih.gov
- RefSELECT trial summary: American College of Cardiologyacc.org
- RefLong-term kidney outcomes of semaglutide in SELECT. PMCpmc.ncbi.nlm.nih.gov
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- The GIP Paradox: Why Agonism and Antagonism Both Produce Weight LossTirzepatide activates the GIP receptor. MariTide blocks it. Both produce substantial weight loss alongside GLP-1 agonism, and the field has not resolved why.
- What Is Maridebart Cafraglutide? Antibody Meets PeptideMariTide is a monoclonal antibody blocking the GIP receptor, conjugated to two GLP-1 agonists. An unusual format, and the opposite premise to tirzepatide.
- Lean Mass Loss on GLP-1 Therapy, and the BELIEVE ResultA substantial share of weight lost on GLP-1 therapy is lean mass. The BELIEVE trial cut lean loss from 7.4% to 2.9% by adding bimagrumab to semaglutide.
- What Is Cagrilintide? The Amylin Half of CagriSemaCagrilintide is a long-acting amylin analogue engineered for weekly dosing. Why native amylin could never be a drug, and what the analogue changed.
- What Is Exenatide? From Gila Monster Venom to MedicineExenatide is a synthetic version of exendin-4, found in Gila monster venom. Why a lizard peptide resists DPP-4 when human GLP-1 does not.